CRN09682

PreclinicalSmall molecule

CCrinetics Pharmaceuticals Inc.

CRN09682 is one of 4 small molecule programs targeting Neuroendocrine Neoplasms. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Neuroendocrine NeoplasmsRecruiting

Neuroendocrine NeoplasmsPreclinical

Recruiting

Competition

Competitive Landscape

4 competitors in Neuroendocrine Neoplasms

#DrugCompanyPhaseTrials

Paraplatin

AAvyxa

Phase 1

1 2

Vepesid

AAvyxa

Phase 1

1 3

Platinol

MMcNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.

Phase 1

1 4

CRN09682

CCrinetics Pharmaceuticals Inc.

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2029

PreclinicalRecruiting

Neuroendocrine Neoplasms

NCT07129252

Clinical

Trials by Indication[1]

Neuroendocrine Neoplasms1 trial

A Phase 1/2 Dose Escalation Study of CRN09682 With an Expansion Phase in Participants With Progressive Metastatic Somatostatin Receptor Type 2 (SST2)-Expressing Neuroendocrine Neoplasms (NENs) and Other SST2-Expressing Solid Tumors

Recruiting·CCrinetics Pharmaceuticals Inc.·Preclinical·NCT07129252·150 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for CRN09682. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — CRN09682 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for CRN09682. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Crinetics Pharmaceuticals Inc. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: CCrinetics Pharmaceuticals Inc.

CRN09682

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q3 2029

Trials by Indication[1]

Neuroendocrine Neoplasms1 trial

References

Drug Info

Quick Facts

Related News